Expression of claudin-6 (CLDN6) in the tissues of gastric cancer patients and its association with clinical pathology and prognosis were investigated. A retrospective analysis was performed on 213 gastric cancer patients diagnosed and surgically treated in the Central Hospital of Zibo from January 2010 to January 2013. Cancer and normal adjacent tissues were obtained from the patients to detect the expression level of CLDN6 using reverse transcription-quantitative PCR (RT-qPCR). The association between the expression level of CLDN6 and the clinical and pathological features, as well as the prognosis of gastric cancer patients was analyzed. The expression level of CLDN6 was significantly lower in gastric cancer tissues than that in adjacent tissues (t=23.350, P<0.001). The expression level of CLDN6 was associated with age, lymph node metastasis, pathological staging, and distant metastasis (P<0.05). In this study, patients were separated into CLDN6 high-expression group (≥1.42) with 107 patients and CLDN6 low-expression group (<1.42) with 106 patients, with the median expression level of CLDN6 as the boundary. The 1-, 2- and 3-year survival rates of patients in the CLDN6 low-expression group were 80.19, 60.38 and 48.11%, respectively, and those in the CLDN6 high-expression group were 87.85, 73.83 and 66.36%, respectively. The survival rate was significantly better in the CLDN6 high-expression group than that in the CLDN6 low-expression group (P=0.009). In conclusion, the expression level of CLDN6 is low in the cancer tissues of gastric cancer patients, and associated with age, lymph node metastasis, pathological staging and distant metastasis. CLDN6 low expression has a certain negative impact on the prognosis of patients, and therefore, shows potential as an important indicator for the prognosis of gastric cancer patients.
Background: Alisma orientalis beverage (AOB) is a Chinese traditional medicine formulated with a diversity of medicinal plants and used for treating metabolic syndrome and atherosclerosis (AS) since time ago. Given the current limited biological research on AOB, the mechanism by which AOB treats AS is unknown. This study investigats the role of AOB-induced gut microbiota regulation in the expansion of AS. Methods: We established an AS model in male apolipoprotein E-deficient (ApoE −/−) mice that are fed with a high-fat diet (HFD), treated with numerous interventions, and evaluated the inflammatory cytokines and serum biochemical indices. The root of the aorta was stained with oil red O, and the proportion of the lesion area was quantified. Trimethylamine N-oxide (TMAO) and trimethylamine (TMA) levels in serum were evaluated through liquid chromatography with mass spectrometry. Flavin−containing monooxygenase 3 (FMO3) liver protein expression was assessed by Western blotting. 16S rDNA sequencing technique was adopted to establish the changes in the microbiota structure. Results: After 8 weeks of HFD feeding, an inflammatory cytokine, and AS development expression were significantly decreased in mice treated with AOB; the same parameters in the mice treated with the antibiotics cocktail did not change. In the gut microbiota study, mice treated with AOB had a markedly different gut microbiota than the HFD-fed mice. Additionally, AOB also decreased serum TMAO and hepatic FMO3 expression. Conclusion: The antiatherosclerotic effects of AOB were found associated with changes in the content of gut microbiota and a reduction in TMAO, a gut microbiota metabolite, suggesting that AOB has potential therapeutic value in the treatment of AS.
Protracted alcohol withdrawal symptoms (PAWS), characterized by the presence of substance-specific signs and symptoms (including anxiety, irritability, mood instability, insomnia, and cravings), make alcohol abstinence difficult and increase the risk of relapse in recovering alcoholics. The goal of this study was to evaluate the effect of transcutaneous auricular vagus nerve stimulation (taVNS) on PAWS and plasma brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and leptin levels in patients with alcohol dependency. A total of 114 patients with alcohol dependence were randomly divided into two groups: the treatment group and the control group. The patients in the treatment group were treated with taVNS of the bilateral auricular concha using an ear vagus nerve stimulator. The Pennsylvania Alcohol Craving Scale was used to evaluate the extent of craving for alcohol. The Self-Rating Anxiety Scale and Self-Rating Depression Scale (SDS) were used to evaluate the extent of anxiety and depression symptoms, respectively. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality. Enzyme-linked immunosorbent assay was used to measure plasma BDNF, IL-6, TNF-α, and leptin levels. The results showed that the SDS and PSQI scores were significantly lower in the treatment group than in the control group. Moreover, compared with the control group, the average BDNF levels in the treatment group were significantly increased. These results suggest that taVNS could improve the depression symptoms and sleep quality in alcohol-dependent patients after withdrawal, which might be related to the upregulation of plasma BDNF levels.
Background: Hepatocellular carcinoma (HCC) is a highly malignant cancer which lack of effective diagnosis and prognosis biomarkers, therefore surging studies focused on the metabolite candidates for HCC. The current study was designed to systematically review the metabolic studies for HCC, summarize the current available evidence and provide implication for further studies within this area. By systematically screening Pubmed and Embase, and eligibility assessment, we eventually included 55 pieces of studies. After summarized their characteristics, we reviewed them by 3 parts, regarding to the different biofluid they carried out the experiments. By collecting the candidates from all the included studies, we carried out pathway enrichment to see the representative of the reported candidates, as expected the pathway consistent with the current knowledge of HCC. Next, we conduct quality assessment on the included studies. Only 36% of the current evidence grouped as high quality, indicating the quality of metabolic studies needs further improvement.
In the present study, the IER3 expression was examined in tumor tissue from PHC patients to determine whether the IER3 expression is correlated with other clinicopathological parameters. Materials and Methods Sample selectionSixty-two pathologically conformed human HCC specimens without preoprative therapy, such as chemotherapy and radiotherapy, were collected at the pathology department of Zibo center hospital. All specimens were fixed in bufered 4% para formaldehyde, embedded in paraffin. The procedures were performed according to the national institutes of health guidelines regarding the use of human tissues and the study was approved from the review board of the ethics committee of Zibo center hospital. RNA isolation and cDNA conversionRNA was extracted from FFPE tissues using the Relia prep TM FFPE total RNA Miniprep system and based on the manufacturer's recommendation (Promega, 1002). Briefly, six shaving 10 μm thick from a paraffin block of tissue were deparaffinized by washing the tissue with xylene. Tissue was then digested in protease K and allowed to adhere to the RNA biding column.
Background: The efficacy of adjuvant chemotherapy for locally advanced lung cancer cannot be assessed during the treatment, since there is no measurable lesion after surgical resection. We conducted a prospective clinical trial according to the results of drug sensitivity test with an aim to individualize adjuvant chemotherapy. Methods: Patients with resectable c-Stage IB-IIIA nonsmall cell lung cancer were registered between 2005 and
BackgroundSleep disturbance is one of the most prominent complaints of patients with alcohol use disorder (AUD), with more than 70% of patients with AUD reporting an inability to resolve sleep problems during abstinence. Mindfulness-based stress reduction (MBSR) has been shown to improve sleep quality and as an alternative therapy to hypnotics for sleep disorders.ObjectiveThe aim of the present study was to evaluate the effect of short-term MBSR on sleep quality in male patients with AUD after withdrawal.MethodsA total of 91 male patients with AUD after 2 weeks of routine withdrawal therapy were randomly divided into two groups using a coin toss: the treatment group (n = 50) and the control group (n = 41). The control group was received supportive therapy, and the intervention group added with MBSR for 2 weeks on the basis of supportive therapy. Objective sleep quality was measured at baseline and 2 weeks after treatment using the cardiopulmonary coupling (CPC). Indicators related to sleep quality include total sleep time, stable sleep time, unstable sleep time, rapid eye movement (REM) sleep time, wake-up time, stable sleep latency, sleep efficiency, and apnea index. These indicators were compared by an analysis of covariance (ANCOVA) between the two groups, controlling for individual differences in the respective measures at baseline.ResultsThe results showed that there were no significant differences in the age [t (89) = –0.541, P = 0.590), BMI [t (89) = –0.925, P = 0.357], educational status [t (89) = 1.802, P = 0.076], years of drinking [t (89) = –0.472, P = 0.638), daily intake [t (89) = 0.892, P = 0.376], types of alcohol [χ2 (1) = 0.071, P = 0.789], scores of CIWA-AR [t (89) = 0.595, P = 0.554], scores of SDS [t (89) = –1.151, P = 0.253), or scores of SAS [t (89) = –1.209, P = 0.230] between the two groups. Moreover, compared with the control group, the total sleep time [F (1.88) = 4.788, P = 0.031) and stable sleep time [F (1.88) = 6.975, P = 0.010] were significantly increased in the treatment group. Furthermore, the average apnea index in the patients who received MBSR was significantly decreased than in the control group [F (1.88) = 5.284, P = 0.024].ConclusionThese results suggest that short-term MBSR could improve sleep quality and may serve as an alternative treatment to hypnotics for sleep disturbance in patients with AUD after withdrawal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.